NCT05218759View on ClinicalTrials.gov

Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

NANot yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 21, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

October 31, 2025

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Anlotinib

anlotinib administration at a dose of 10 mg daily

Sponsors

Collaborators (1)

3D Medicines
All Listed Sponsors
collaborator

3D Medicines

INDUSTRY

lead

Shanghai Chest Hospital

OTHER